trending Market Intelligence /marketintelligence/en/news-insights/trending/wcsara2dwxvaw3iwrcxmha2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

FDA Watch: Approval for Novartis; priority review for Pfizer, Astellas

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


FDA Watch: Approval for Novartis; priority review for Pfizer, Astellas

Approvals and designations made by the U.S. Food and Drug Administration for the week ended March 23.

Approvals

* Novartis AG's Tasigna, for children one year of age or older with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase, or Ph+ CML-CP. The drug is already approved to treat adults and children with Ph+ CML-CP resistant or intolerant to prior tyrosine kinase inhibitor therapy and prior therapy.

* Orthofix International NV's G-Beam fusion beaming system, for Charcot foot. The company received 510(k) clearance.

* Sun Pharmaceutical Industries Ltd.'s Ilumya, for moderate to severe plaque psoriasis.

* Seattle Genetics Inc.'s Adcetris-chemotherapy combination, for adults with previously untreated stage 3 or 4 classical Hodgkin lymphoma. The drug is already approved to treat three other types of lymphoma as well as certain patients with mycosis fungoides. Seattle Genetics is developing Adcetris with Takeda Pharmaceutical Co. Ltd.

* Restoration Robotics Inc.'s Artas hair transplantation system, for pattern baldness. The company received 510(k) clearance.

SNL Image
FDA headquarters in Silver Spring, Md.
Source: Associated Press

Priority review

* Pfizer Inc. and Astellas Pharma Inc.'s Xtandi, for patients with castration-resistant prostate cancer that has not spread to other parts of the body. The drug is already approved to treat certain patients with castration-resistant prostate cancer.

Fast track

* Fennec Pharmaceuticals Inc.'s Pedmark, to prevent ototoxicity, or ear damage, as a side-effect of cisplatin chemotherapy in children with standard-risk hepatoblastoma.

Other designations: orphan drug

* Trillium Therapeutics Inc.'s TTI-621, for cutaneous T-cell lymphoma.

* Cellectar Biosciences Inc.'s CLR 131, for neuroblastoma. The company is evaluating the drug in other indications, including multiple myeloma.